炔诺孕酮结构式
|
常用名 | 炔诺孕酮 | 英文名 | Levonorgestrel |
|---|---|---|---|---|
| CAS号 | 6533-00-2 | 分子量 | 312.446 | |
| 密度 | 1.1±0.1 g/cm3 | 沸点 | 459.1±45.0 °C at 760 mmHg | |
| 分子式 | C21H28O2 | 熔点 | 239-241ºC | |
| MSDS | N/A | 闪点 | 195.4±21.3 °C |
炔诺孕酮用途Norgestrel 是孕酮的合成类似物,是口服避孕药中常见的化合物,也是一种强大的神经保护性抗氧化剂,可防止光诱导的感光细胞中的 ROS 的生成以及细胞死亡。 |
| 中文名 | 炔诺孕酮 |
|---|---|
| 英文名 | levonorgestrel |
| 中文别名 | DL-甲基炔诺酮 | 18-甲基炔诺酮 | 高诺酮 |
| 英文别名 | 更多 |
| 描述 | Norgestrel 是孕酮的合成类似物,是口服避孕药中常见的化合物,也是一种强大的神经保护性抗氧化剂,可防止光诱导的感光细胞中的 ROS 的生成以及细胞死亡。 |
|---|---|
| 相关类别 | |
| 体外研究 | Norgestrel(20μM;24小时;661W细胞)处理显着增加血清剥夺后的细胞活力,因此证明Norgestrel对应激的661W细胞具有神经保护作用[1]。Norgestrel(20μM;24小时;661W细胞)处理减少细胞凋亡诱导的PARP和caspase-3裂解[1]。Norgestrel(20μM;6小时;661W细胞)处理bFGF导致光感受器细胞中bFGF mRNA的显着上调[1]。细胞活力测定[1]细胞系:661W细胞浓度:20μM孵育时间:24小时结果:血清剥夺后细胞活力显着增加。蛋白质印迹分析[1]细胞系:661W细胞浓度:20μM孵育时间:24小时结果:凋亡诱导的PARP和caspase-3裂解减少。RT-PCR[1]细胞系:661W细胞浓度:20μM孵育时间:6小时结果:1小时内bFGF mRNA显着上调。 |
| 体内研究 | Norgestrel(100mg/kg;腹膜内注射;6,24或48小时;Balb/c小鼠)治疗可以预防光感受器细胞中光诱导的ROS,以及随后的细胞死亡。Norgestrel通过主要抗氧化转录因子Nrf2的翻译后调节起作用;引起其磷酸化,随后的核转位,并增加其效应蛋白超氧化物歧化酶2(SOD2)的水平[2]。动物模型:Balb/c小鼠出生并维持在昏暗的循环光中[2]剂量:100 mg/kg;给药:腹腔注射;6,24或48小时结果:通过丝氨酸40磷酸化增加Nrf2的表达和活化,增加其靶抗氧化剂超氧化物歧化酶2(SOD2)的表达,并减少线粒体氧化应激。 |
| 参考文献 |
| 密度 | 1.1±0.1 g/cm3 |
|---|---|
| 沸点 | 459.1±45.0 °C at 760 mmHg |
| 熔点 | 239-241ºC |
| 分子式 | C21H28O2 |
| 分子量 | 312.446 |
| 闪点 | 195.4±21.3 °C |
| 精确质量 | 312.208923 |
| PSA | 37.30000 |
| LogP | 3.92 |
| InChIKey | WWYNJERNGUHSAO-QHOCJJNXSA-N |
| SMILES | C#CC1(O)CCC2C3CCC4=CC(=O)CCC4C3CCC21CC |
| 外观性状 | 白色结晶粉末 |
| 蒸汽压 | 0.0±2.6 mmHg at 25°C |
| 折射率 | 1.571 |
| 储存条件 | 2-8°C |
| 危害码 (欧洲) | Xn:Harmful |
|---|---|
| 风险声明 (欧洲) | R20/21/22;R40 |
| 安全声明 (欧洲) | S22-S36 |
| 危险品运输编码 | NONH for all modes of transport |
| WGK德国 | 3 |
| RTECS号 | JF8259000 |
|
Progestagen-only oral contraceptives: a preliminary report of the action and clinical use of norgestrel and norethisterone.
Drugs 6(3) , 169-81, (1973)
|
|
|
Types of combined oral contraceptives used by US women.
Contraception 86(6) , 659-65, (2012) We sought to estimate the prevalence of types of combined oral contraceptives (COCs) used among US women.We analyzed interview-collected data from 12,279 women aged 15-44 years participating in the Na... |
|
|
Newer non-oral hormonal contraception.
BMJ 346 , f341, (2013)
|
|
实验名称:NCI human tumor cell line growth inhibition assay. Data for the MCF7 Non-Small Cell L...
来源:DTP/NCI
靶标:N/A
External Id:MCF7_OneDose
|
|
实验名称:Primary high throughput screening by co-culture imaging for identification hits as a ...
来源:23209
靶标:N/A
External Id:UIHTS20180925
|
|
实验名称:Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in H...
来源:Southern Research Institute
靶标:CFTR
External Id:CF Folding
|
|
实验名称:Cell-based high throughput primary assay to identify activators of GPR151
来源:The Scripps Research Institute Molecular Screening Center
靶标:RecName: Full=G-protein coupled receptor 151; AltName: Full=G-protein coupled receptor PGR7; AltName: Full=GPCR-2037; AltName: Full=Galanin receptor 4; AltName: Full=Galanin-receptor-like protein; Short=GalRL
External Id:GPR151_PHUNTER_AG_LUMI_1536_1X%ACT
|
|
实验名称:AlphaScreen-based biochemical high throughput primary assay to identify activators of...
来源:The Scripps Research Institute Molecular Screening Center
靶标:N/A
External Id:FBW7_ACT_ALPHA_1536_1X%ACT PRUN
|
|
实验名称:AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of...
来源:The Scripps Research Institute Molecular Screening Center
External Id:MITF_INH_Alpha_1536_1X%INH PRUN
|
| (8R,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one |
| Mirena |
| 13-Ethyl-17-ethynyl-17b-hydroxy-4-gonen-3-one |
| 17a-Ethynyl-18-homo-19-nortestosterone |
| Norgeston |
| 13b-Ethyl-17a-ethynyl-17b-hydroxygon-4-en-3-one |
| 18-METHYLNORETHINDRONE |
| 18-Methyl-17a-ethynyl-19-nortestosterone |
| (−)-Norgestrel |
| Norplant |
| (17a)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one |
| Levonelle |
| 13-β-ETHYL-17-α-ETHYNYL-17-β-HYDROXYGON-4-EN-3-ONE |
| monovar |
| MFCD01546387 |
| sh850 |
| wy3707 |
| 17b-Hydroxy-18-methyl-19-nor-17a-pregn-4-en-20-yn-3-one |
| (8R,9S,10R,13S,14S,17R)-17-Ethinyl-13-ethyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-on |
| Levonova |
| (8R,9S,10R,13S,14S,17R)-13-éthyl-17-éthynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tétradécahydro-3H-cyclopenta[a]phénanthrén-3-one |
| 17a-Ethynyl-18-methyl-19-nortestosterone |
| EINECS 212-349-8 |
| 17a-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one |
| D-Norgestrel |
| Microval |
| 13-Ethyl-17-hydroxy-18,19-dinor-17a-pregn-4-en-20-yn-3-one |
| Norgestrel |
| 17a-Ethynyl-13-ethyl-19-nortestosterone |
| Microlut |
| Ovrette |
| UNII:3J8Q1747Z2 |
| D(−)-Norgestrel |
| NorLevo |
| (17a)-(-)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one |
| D-(-)-Norgestrel |
| Neogest |
| (-)-Norgestrel |
| 13-Ethyl-17a-ethynyl-17-hydroxygon-4-en-3-one |
| fh122-a |